Empowered Patient Podcast

John Mulcahy PhD, President and CEO, SiteOne Therapeutics talks about broadening their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching. Approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain. Stopping the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medication like opioids. Lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.

#pain #hypersensitivity #sodiumchannels #opioids

SiteOneTherapeutics.com

Listen to the podcast here

John Mulcahy PhD, President and CEO, SiteOne Therapeutics talks about broadening their pipeline from acute pain to hypersensitivity disorders like chronic cough and itching. Approach is to inhibit voltage-gated subtype sodium channel Nav1.7, a genetically validated target for pain. Stopping the pain signal in the peripheral nervous system before it gets to the spinal cord avoids some of the liabilities with existing pain medication like opioids. Lead candidate is now an intravenous analgesic showing proof of concept for the treatment of acute pain and itch.

#pain #hypersensitivity #sodiumchannels #opioids

SiteOneTherapeutics.com

Download the transcript here

Michael McCullar, CEO and Hong Tang, Co-Founder and Chief Medical Officer OnQuality Pharmaceuticals describe the pipeline they are building to address unmet clinical needs in the area of oncology supportive care for skin rashes such as Hand-Foot Skin Reaction and GI toxicities like chemotherapy-induced diarrhea. As leaders in the emerging oncodermatology and oncogastroenterology fields, the mission is to develop cancer supportive care drugs to deal with the most common toxicities to make it easier for patients to tolerate their cancer treatments.

@OnQualityRx #cancer #cancertherapy #cancerresearch #chemotherapy #supportivecare #cancertherapeutics #pharma

OnQualityRx.com

Listen to the podcast here

Michael McCullar, CEO and Hong Tang, Co-Founder and Chief Medical Officer OnQuality Pharmaceuticals describe the pipeline they are building to address unmet clinical needs in the area of oncology supportive care for skin rashes such as Hand-Foot Skin Reaction and GI toxicities like chemotherapy-induced diarrhea. As leaders in the emerging oncodermatology and oncogastroenterology fields, the mission is to develop cancer supportive care drugs to deal with the most common toxicities to make it easier for patients to tolerate their cancer treatments.

@OnQualityRx #cancer #cancertherapy #cancerresearch #chemotherapy #supportivecare #cancertherapeutics #pharma

OnQualityRx.com

Download the transcript here

Richard Brand, Chief Financial Officer, DiaCarta discusses precision molecular diagnostics that are being used for early detection of cancer. By using liquid biopsy technology, blood draw can be used for early detection and monitoring of people who have cancer and avoiding the need for a physical biopsy. Also a radiation therapy and chemotherapy tests are supporting personalized medicine for those undergoing treatment who are at the extreme tails of the population - either very sensitive to it or have a very robust response - so as to better determine appropriate dosage.

@DiaCarta_DX #DiaCarta #liquidbiopsy #earlycancerdetection #precisionmedicine #personalizedmedicine #coloncancer

DiaCarta.com

Listen to the podcast here

Richard Brand, Chief Financial Officer, DiaCarta discusses precision molecular diagnostics that are being used for early detection of cancer. By using liquid biopsy technology, blood draw can be used for early detection and monitoring of people who have cancer and avoiding the need for a physical biopsy. Also a radiation therapy and chemotherapy tests are supporting personalized medicine for those undergoing treatment who are at the extreme tails of the population - either very sensitive to it or have a very robust response - so as to better determine appropriate dosage.

@DiaCarta_DX #DiaCarta #liquidbiopsy #earlycancerdetection #precisionmedicine #personalizedmedicine #coloncancer

DiaCarta.com

Download the transcript here

Rick Anderson, President and General Manager of North America, DarioHealth discusses how the company is leading the way on digital therapeutics combining digital technologies, artificial intelligence, software, and human coaching to help people manage chronic conditions including hypertension, diabetes, obesity and back pain. Patients are getting digital coaching, specific suggestions, feedback and support on the device of their choice through dynamic personalized programs. Studies across a variety of conditions are showing consistent improvement, maintenance, and significant reduction in pain.

@DarioHealth #ChronicConditionManagement #DigitalHealth #AI #DigitalTherapeutics #BackPain #Diabetes #DiabetesManagement

DarioHealth.com

Listen to the podcast here

Rick Anderson, President and General Manager of North America, DarioHealth discusses how the company is leading the way on digital therapeutics combining digital technologies, artificial intelligence, software, and human coaching to help people manage chronic conditions including hypertension, diabetes, obesity and back pain. Patients are getting digital coaching, specific suggestions, feedback and support on the device of their choice through dynamic personalized programs. Studies across a variety of conditions are showing consistent improvement, maintenance, and significant reduction in pain.

@DarioHealth #ChronicConditionManagement #DigitalHealth #AI #DigitalTherapeutics #BackPain #Diabetes #DiabetesManagement

DarioHealth.com

Download the transcript here

Ron Chiarello PhD, Founder, CEO and Chairman of the Board, Alveo Technologies talks about the need for a low-cost, easy-to-use diagnostic platform to allow more people to detect and manage an infectious disease like COVID-19. Winning the XPRIZE Rapid COVID-19 Testing Competition has highlighted their be.well diagnostic platform which uses an at-home system to take a nasal swab that gets placed in a disposable cartridge that goes into an analyzer that communicates to a mobile device with RNA-based test results in less than 30 minutes.

#COVID19 #COVIDVaccine #COVIDTesting #InfectiousDisease #PublicHealth

AlveoTechnologies.com

Listen to the podcast here

Ron Chiarello PhD, Founder, CEO and Chairman of the Board, Alveo Technologies talks about the need for a low-cost, easy-to-use diagnostic platform to allow more people to detect and manage an infectious disease like COVID-19. Winning the XPRIZE Rapid COVID-19 Testing Competition has highlighted their be.well diagnostic platform which uses an at-home system to take a nasal swab that gets placed in a disposable cartridge that goes into an analyzer that communicates to a mobile device with RNA-based test results in less than 30 minutes.

#COVID19 #COVIDVaccine #COVIDTesting #InfectiousDisease #PublicHealth

AlveoTechnologies.com

Download the transcript here